Drugs & Aging

, Volume 14, Issue 1, pp 41–54 | Cite as

Behavioural Problems Associated With Dementia

The Role of Newer Antipsychotics
  • Gabriela Stoppe
  • Claudia A. Brandt
  • Jürgen H. Staedt
Review Article


Behavioural disorders are a common feature in dementia, especially in the later stages of the disease. The most frequent disorders are agitation, aggression, paranoid delusions, hallucinations, sleep disorders, including nocturnal wandering, incontinence and (stereotyped) vocalisations or screaming. Behavioural disorders, rather than cognitive disorders, are the main reason why caregivers place patients with dementia in a nursing home. However, although behavioural disorders are important, there is still no international agreement with respect to the description and definition of symptoms and syndromes. This also holds true for the wide variety of scales for quantification and measurement of behavioural disorders.

Drug therapy should be considered after possible underlying causes such as physical illness, drug adverse effects and environmental Stressors have been ruled out, or specifically addressed, and a behavioural approach has also failed. This article briefly reviews the evidence for non-antipsychotic drug therapies, which include a variety of substances. However, antipsychotics are the group of drugs which have been most frequently studied for the treatment of behavioural syndromes in dementia. Drug responsive symptoms include anxiety, verbal and physical agitation, hallucinations, delusions, uncooperativeness and hostility, whereas wandering, hoarding, unsociability, poor self-care, screaming and other stereotyped behaviour seem to be unresponsive to all drugs.

Although the use of classical antipsychotics is limited by extrapyramidal symptoms, anticholinergic adverse effects, sedation and postural hypotension, the newer antipsychotics offer the chance of a better risk : benefit ratio. This article reviews the small amount of data published on the use of the newer antipsychotics, and concludes that risperidone at low dosages (0.5 to 2 mg/day) seems to be especially useful for the treatment of behavioural symptoms in dementia because of its negligible anticholinergic adverse effects. The use of clozapine is limited by its anticholinergic activity, at least in dementia of the Alzheimer and Lewy body types. However, in patients with psychosis arising from Parkinson’s disease it seems to be the drug of choice, and similar activity is likely for olanzapine. There are no published data on other newer drugs, such as sertindole, quetiapine or ziprasidone.

Future studies should also address questions of dementia heterogeneity and should compare different drug treatments and treatment combinations.


Dementia Adis International Limited Clozapine Risperidone Olanzapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ott A, Breteler M, van Harskamp F, et al. Prevalence of Alzheimers disease and vascular dementia: association with education: the Rotterdam Study. BMJ 1995; 310: 970–3PubMedGoogle Scholar
  2. 2.
    Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551–6PubMedGoogle Scholar
  3. 3.
    Morgan K, Lilley JM, Arie T, et al. Incidence of dementia in a representative British sample. Br J Psychiatry 1993; 163: 467–70PubMedGoogle Scholar
  4. 4.
    Rovner BW, German PS, Broadhead J, et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatr 1990; 2: 13–24PubMedGoogle Scholar
  5. 5.
    Tariot PN, Podgorski CA, Blazina L, et al. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150: 1063–9PubMedGoogle Scholar
  6. 6.
    Skoog I, Nilsson L, Palmertz B, et al. A population based study of dementia in 85 year-olds. N Engl J Med 1993; 328: 153–8PubMedGoogle Scholar
  7. 7.
    Rapp MS, Flint AJ, Herrman N, et al. Behavioural disturbances in the demented elderly: phenomenology, pharmacotherapy and behavioural management. Can J Psychiatry 1992; 37: 651–7PubMedGoogle Scholar
  8. 8.
    Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimers disease: phenomenology and treatment. J Clin Psychiatry 1987; 5 Suppl. 9–15Google Scholar
  9. 9.
    Beck C, Frank L, Chumbler NR, et al. Correlates of disruptive behavior in severely cognitively impaired nursing home residents. Gerontologist 1998; 38: 189–98PubMedGoogle Scholar
  10. 10.
    Pruchno RA, Michaels JE, Potashnik S. Predictors for institutionalization among Alzheimer disease victims with caregiving spouses. J Gerontol 1990; 45Suppl. 6: 259–66Google Scholar
  11. 11.
    O’Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5: 45–52PubMedGoogle Scholar
  12. 12.
    Class CA, Schneider L, Farlow MR. Optimal management of behavioural disorders associated with dementia. Drugs Aging 1997; 10: 95–106PubMedGoogle Scholar
  13. 13.
    Cohen-Mansfield J, Werner P. Longitudinal changes in behavioral problems in old age: a study in an adult day care population. J Gerontol A Biol Sci Med Sci 1998; 53: M65–71PubMedGoogle Scholar
  14. 14.
    Haupt M, Janner M, Stierstorfer A, et al. Das Erscheinungsbild und die Verlaufs Stabilitat von nicht-kognitiven Symptommustern bei Patienten mit Alzheimerscher Krankheit. Fortschr Neurol Psychiatr 1998; 66: 233–40PubMedGoogle Scholar
  15. 15.
    Rovner BW. Behavioral and psychiatric disability in Alzheimers disease. J Geriatr Psychiatry 1992; 25: 247–55Google Scholar
  16. 16.
    Butler FR, Burgio LD, Engel BT. Neuroleptics and behavior: a comparative study. J Gerontol Nurs 1987; 13: 15–9PubMedGoogle Scholar
  17. 17.
    Everitt DE, Fields DR, Soumerai SS, et al. Resident behavior and staff distress in the nursing home. J Am Geriatr Soc 1991; 39: 792–8PubMedGoogle Scholar
  18. 18.
    Swearer JM, Drachman DA, ODonnell BF, et al. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36: 784–90PubMedGoogle Scholar
  19. 19.
    Merriam AE, Aronson MK, Gasten P, et al. The psychiatric symptoms of Alzheimers disease. J Am Geriatr Soc 1988; 36: 7–12PubMedGoogle Scholar
  20. 20.
    Teri L, Borson S, Kiyak A, et al. Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimers disease. J Am Geriatr Soc 1989; 37: 109–16PubMedGoogle Scholar
  21. 21.
    Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimers disease: IV. disorders of behaviour. Br J Psychiatry 1990; 157: 1063–9Google Scholar
  22. 22.
    Devanand DP, Brockington CD, Moody BJ. Behavioral syndromes in Alzheimers disease. Int Psychogeriatrics 1992; 4: 161–84Google Scholar
  23. 23.
    OLeary PA, Haley WE, Paul PB. Behavioral assessment in Alzheimers disease: use of a 24-hr log. Psychol Aging 1993; 8: 139–43Google Scholar
  24. 24.
    Riter RN, Fries BE. Predictors of the placement of cognitively impaired residents on special care units. Gerontologist 1992; 32: 184–90PubMedGoogle Scholar
  25. 25.
    Wagner AW, Teri L, Orr-Rainey N. Behavior problems of residents with dementia in special care units. Alzheimer Dis Assoc Disord 1995; 9: 121–7PubMedGoogle Scholar
  26. 26.
    Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimers disease. Arch Neurol 1989; 46: 854–7PubMedGoogle Scholar
  27. 27.
    Yeager BF, Farnett LE, Ruzicka SA. Management of the behavioral manifestations of dementia. Arch Intern Med 1995; 155: 250–60PubMedGoogle Scholar
  28. 28.
    Raskind MA. Management of late life depression and the non-cognitive behavioral disturbances of Alzheimers disease. Psychiatr Clin North Am 1993; 16: 815–27PubMedGoogle Scholar
  29. 29.
    Cohen-Mansfield J. Agitated behaviors in the elderly, II: preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34: 722–7PubMedGoogle Scholar
  30. 30.
    Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry 1996; 57Suppl. 7: 55–63PubMedGoogle Scholar
  31. 31.
    Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioural disturbances on Alzheimers disease. Neuropsych Neuropsychol Behav Neurol 1993; 6: 229–34Google Scholar
  32. 32.
    Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465–73PubMedGoogle Scholar
  33. 33.
    Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998; 50: 1222–30PubMedGoogle Scholar
  34. 34.
    Katz IR, Rovner B. Psychiatric disorders in the nursing home: a selective review of studies related to clinical care. Int J Geriatr Psychiatry 1993; 8: 75–87Google Scholar
  35. 35.
    McKhann G, Drachmann D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44PubMedGoogle Scholar
  36. 36.
    Blacker D, Albert MS, Bassett S, et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimers disease. Arch Neurol 1994; 51: 1198–204PubMedGoogle Scholar
  37. 37.
    Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60PubMedGoogle Scholar
  38. 38.
    McKeith IG, Perry RH, Fairbairn AF, et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22: 911–22PubMedGoogle Scholar
  39. 39.
    McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and interrater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44: 872–7PubMedGoogle Scholar
  40. 40.
    McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines of the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996; 47: 1113–24PubMedGoogle Scholar
  41. 41.
    The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416–8Google Scholar
  42. 42.
    Miller BL, Ikonte C, Ponton M, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 1997; 48: 937–42PubMedGoogle Scholar
  43. 43.
    Pasquier F, Petit H. Frontotemporal dementia: its rediscovery. Eur Neurol 1997; 38: 1–6PubMedGoogle Scholar
  44. 44.
    McKeith IG, Fairbairn AF, Perry RH, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–8PubMedGoogle Scholar
  45. 45.
    McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346: 699PubMedGoogle Scholar
  46. 46.
    Ballard CG, Grace J, McKeith IG, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimers disease. Lancet 1998; 351: 1032–3PubMedGoogle Scholar
  47. 47.
    Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimers disease. Neuroreport 1994; 5: 747–9PubMedGoogle Scholar
  48. 48.
    Wilcock GK, Scott M. Tacrine for senile dementia of Alzheimers or Lewy body type [abstract]. Lancet 1994; 344: 544PubMedGoogle Scholar
  49. 49.
    Stewart JT. Managing the care of patients with dementia: how to maximize level of functioning and minimize behavioral problems. Postgrad Med 1991; 90: 45–9PubMedGoogle Scholar
  50. 50.
    Sunderland T. Treatment of the elderly suffering from psychosis and dementia. J Clin Psychiatry 1996; 57Suppl. 9: 53–6PubMedGoogle Scholar
  51. 51.
    Zayas EM, Grossberg GT. Treating the agitated Alzheimer patient. J Clin Psychiatry 1996; 57Suppl. 7: 46–51PubMedGoogle Scholar
  52. 52.
    Taft L, Delaney K, Seman D, et al. Creating a therapeutic milieu in dementia care. J Gerontol Nurs 1993; 19: 30–9PubMedGoogle Scholar
  53. 53.
    Mintzer JE, Lewis L, Pennypacker L, et al. Behavioral intensive care unit (BICU): a new concept in management of acute agitated behavior in elderly demented patients. Gerontologist 1993; 33: 801–6PubMedGoogle Scholar
  54. 54.
    Mace N, Rabins PV. The 36-hour day: a family guide to caring for persons with Alzheimers disease, related dementing illnesses and memory loss in later life. Baltimore (MD): Johns Hopkins University Press, 1991Google Scholar
  55. 55.
    Rovner BW, Steele CD, Shmuely Y, et al. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc 1996; 44: 7–13PubMedGoogle Scholar
  56. 56.
    Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging. Arch Neurol 1974; 30: 113–21PubMedGoogle Scholar
  57. 57.
    Perry EK, Tomlinson BE, Blessed G. Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. BMJ 1978 II: 1457–9Google Scholar
  58. 58.
    Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47: 209–14PubMedGoogle Scholar
  59. 59.
    Palmer AM, Stratman GC, Procter AW, et al. Possible neurotransmitter basis of behavioral changes in Alzheimer disease. Ann Neurol 1988; 23: 6161–20Google Scholar
  60. 60.
    Eichelman B. Neurochemical basis of aggressive behavior. Psychiatric Ann 1987; 17: 371–4Google Scholar
  61. 61.
    Eichelman B. Toward a rational pharmacotherapy for aggressive and violent behavior. Hosp Community Psychiatry 1988; 39: 31–9PubMedGoogle Scholar
  62. 62.
    Ellison DW, Deal MF, Mazurek MF, et al. A post-mortem study of amino acid neurotransmitters in Alzheimer disease. Ann Neurol 1986; 20: 616–21PubMedGoogle Scholar
  63. 63.
    Hardy J, Cowburn R, Barton A, et al. A disorder of cortical GABAergic innervation in Alzheimer disease. Neurosci Lett 1987; 73: 192–6PubMedGoogle Scholar
  64. 64.
    Murray MA, Peskind ER. Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alz Dis Assoc Disord 1994; 8Suppl. 3: 54–60Google Scholar
  65. 65.
    Elrod R, Peskind ER, DiGiacomo L, et al. Effects of Alzheimer’s disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997; 154: 25–30PubMedGoogle Scholar
  66. 66.
    Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry 1997; 42: 1016–23PubMedGoogle Scholar
  67. 67.
    Herrmann N, Lanctot KL, Naranjo CA. Behavioural disorders in demented elderly patients: current issues in pharmacotherapy. CNS Drugs 1996; 6: 280–300Google Scholar
  68. 68.
    Weiner MF, Koss E, Wild KV, et al. Measures of psychiatric symptoms in Alzheimer patients: a review. Alzheimer Dis Assoc Disord 1996; 10(1): 20–30PubMedGoogle Scholar
  69. 69.
    Reisberg B. Behavioral pathology in Alzheimers disease rating scale (BEHAVE-AD). J Clin Psychiatry 1987; 48 Suppl: 9–15PubMedGoogle Scholar
  70. 70.
    Allen RL, Walker Z, D’Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995; 346: 185PubMedGoogle Scholar
  71. 71.
    Brecher M, Clyde MS, the Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Poster presented at the Eighth Congress of the International Psychogeriatric Association. Jerusalem, Israel, Aug 17–22, 1997Google Scholar
  72. 72.
    De Deyn P, De Smedt G, the Risperidone Working Group. Risperidone in the treatment of behavioral disturbances in dementia. Poster presented at the Eighth Congress of the International Psychogeriatric Association. Jerusalem, Israel, Aug 17–22, 1997Google Scholar
  73. 73.
    Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriat 1992; 4: 187–95Google Scholar
  74. 74.
    Honigfeld G, Klett J. The Nurses Observation Scale for Inpatient Evaluation (NOSIE). J Clin Psychol 1965; 21: 65–71PubMedGoogle Scholar
  75. 75.
    Dingemans PM. The Brief Psychiatric Rating Scale (BPRS) and the Nurses Observation Scale for Inpatient Evaluation (NOSIE) in the evaluation of positive and negative symptoms. J Clin Psychol 1990; 46: 168–74PubMedGoogle Scholar
  76. 76.
    Hamot HB, Patin RJ, Singer MJ. Factor structure of the Sandoz Clinical Assessment Geriatric Scale (SCAG). Psychopharmacol Bull 1984; 1984; 20: 142–50PubMedGoogle Scholar
  77. 77.
    Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment Geriatric Scale (SCAG). J Am Geriatr Soc 1974; 22: 107–13PubMedGoogle Scholar
  78. 78.
    Cohen-Mansfield J, Werner P, Marx MS. An observational study of agitation in agitated nursing home residents. Int Psychogeriatr 1989; 1: 153–65PubMedGoogle Scholar
  79. 79.
    Lavretsky H, Sulzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998; 6: 127–35PubMedGoogle Scholar
  80. 80.
    Workman Jr RH, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1997; 9: 594–7PubMedGoogle Scholar
  81. 81.
    Ferris SH, Mackell JA. Behavioral outcomes in clinical trials for Alzheimer disease. Alz Dis Assoc Disord 1997; 11Suppl. 4: S10–15Google Scholar
  82. 82.
    Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986; 143: 35–9PubMedGoogle Scholar
  83. 83.
    Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS). Psychol Rep 1962; 10: 799–812Google Scholar
  84. 84.
    National Institute of Mental Health (NIMH). CGI: clinical global impressions. In: Guy W, editor. EDCEU assessment in psychopharmacology. Rockville (MD): NIMH, 1970; 217–22Google Scholar
  85. 85.
    Herrmann N, Rivard MF, Flynn M, et al. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci 1998; 10: 220–3PubMedGoogle Scholar
  86. 86.
    Geizer M, Ancill RJ. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998; 43: 421–2PubMedGoogle Scholar
  87. 87.
    Gutzmann H, Kühl KP, Kanowski S, et al. Measuring the efficacy of pharmacological treatment of psychomotor restlessness in dementia: clinical evaluation of tiapride. Pharmacopsychiatry 1997; 30: 6–11PubMedGoogle Scholar
  88. 88.
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol 1967; 6: 278–96Google Scholar
  89. 89.
    Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6: 55–64PubMedGoogle Scholar
  90. 90.
    Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 1994; 2: 352–4Google Scholar
  91. 91.
    Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212–6PubMedGoogle Scholar
  92. 92.
    Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimers disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691–708Google Scholar
  93. 93.
    Aisen PS, Johannessen DJ, Marin DB. Trazodone for behavioral disturbance in Alzheimers disease. Am J Geriatr Psychiatry 1993; 1(4): 349–50Google Scholar
  94. 94.
    Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5: 60–9PubMedGoogle Scholar
  95. 95.
    Levy MA, Burgio LD, Sweet R, et al. A trial of buspirone in the control of disruptive behaviors in community-dwelling patients with dementia. Int J Geriatr Psychiatry 1994; 9: 841–8Google Scholar
  96. 96.
    Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo controlled study of trazodone and buspirone in Alzheimers disease. Int J Geriatr Psychiatry 1994; 9: 55–9Google Scholar
  97. 97.
    Goad DL, Davis CM, Liem P, et al. The use of selegeline in Alzheimers patients with behaviour problems. J Clin Psychiatry 1991; 52: 342–5PubMedGoogle Scholar
  98. 98.
    Burke W, Roccaforte WH, Wengel SP, et al. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41: 1219–25PubMedGoogle Scholar
  99. 99.
    Greendyke RM, Kanter DR, Schuster DB, et al. Propanolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis 1986; 174: 290–4PubMedGoogle Scholar
  100. 100.
    Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double blind study. J Clin Psychiatry 1986; 47: 423–6PubMedGoogle Scholar
  101. 101.
    Ratey JJ, Sorgi P, ODriscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind placebo-controlled study. J Clin Psychiatry 1992; 53: 41–6PubMedGoogle Scholar
  102. 102.
    Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimers outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115–8PubMedGoogle Scholar
  103. 103.
    Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160–6PubMedGoogle Scholar
  104. 104.
    Lemke MR. Effects of carbamazepine on agitation in Alzheimers inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56: 354–7PubMedGoogle Scholar
  105. 105.
    Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993; 6: 205–9PubMedGoogle Scholar
  106. 106.
    Sandborn WD, Bendfeldt F, Hamdy R. Valproic acid for physically aggressive behaviour in geriatric patients. Am J Geriatr Psychiatry 1995; 3: 239–42Google Scholar
  107. 107.
    Sival RC, Haffmans PMJ, Van Gent PP, et al. The effects of sodium valproate on disturbed behaviour in dementia. J Am Geriatr Soc 1994; 42: 906–7PubMedGoogle Scholar
  108. 108.
    Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997; 5: 344–51PubMedGoogle Scholar
  109. 109.
    Chesrow EJ, Kaplitz SE, Vetra H, et al. Blind study of oxazepam in the management of geriatric patients with behavioral problems. Clin Lab Med 1965; 72: 1001–5Google Scholar
  110. 110.
    Sanders JF. Evaluation of oxazepam and placebo in emotionally disturbed aged patients. Geriatrics 1965; 20: 739–46PubMedGoogle Scholar
  111. 111.
    Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and risk of hip fracture. N Engl J Med 1987; 316: 363–9PubMedGoogle Scholar
  112. 112.
    Calkin PA, Kunik ME, Orengo CA, et al. Tolerability of clonazepam in demented and non-demented geropsychiatric patients. Int J Geriatr Psychiatry 1997; 12: 745–9PubMedGoogle Scholar
  113. 113.
    Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of non-psychotic symptoms associated with senility. J Am Geriatr Soc 1973; 12: 546–51Google Scholar
  114. 114.
    Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, non-psychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6: 546–59PubMedGoogle Scholar
  115. 115.
    Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of non-cognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147: 1640–5PubMedGoogle Scholar
  116. 116.
    Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimers disease. Pharmacotherapy 1995; 15: 495–501PubMedGoogle Scholar
  117. 117.
    Stoppe G, Sandholzer H, Staedt J, et al. Sleep disturbances in the demented elderly: treatment in ambulatory care. Sleep 1995; 18: 844–8PubMedGoogle Scholar
  118. 118.
    Prien Y, Haber PA, Caffey EM. The use of psychoactive drugs in elderly patients with psychiatric disorders: survey conducted in twelve veterans administration hospitals. J Am Geriatr Soc 1975; 23: 104–12.PubMedGoogle Scholar
  119. 119.
    Michel K, Kolakowska T. A survey of prescribing psychotropic drugs in two psychiatric hospitals. Br J Psychiatry 1981; 138: 217–21PubMedGoogle Scholar
  120. 120.
    Gilleard CJ, Morgan K, Wade BE. Patterns of neuroleptic use among the institutionalized elderly. Acta Psychiatr Scand 1983; 68: 419–25PubMedGoogle Scholar
  121. 121.
    Devanand DP, Sackeim HA, Mayeux R. Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. Compr Psychiatry 1988; 29: 387–401PubMedGoogle Scholar
  122. 122.
    Hesse KA, Driscoll A, Jacobson S. Neuroleptic prescriptions for acutely ill geriatric patients. Arch Intern Med 1993; 153: 2581–7PubMedGoogle Scholar
  123. 123.
    Streim JE. OBRA regulations and psychiatric care in the nursing home. Psychiatric Ann 1995; 25: 413–8Google Scholar
  124. 124.
    Risse SC, Cubberly L, Lampe TH, et al. Acute effects of neuroleptic withdrawal in elderly demented patients. J Geriatr Drug Ther 1989; 2: 65–77Google Scholar
  125. 125.
    Semla TP, Palla K, Poddig B, et al. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42: 648–52PubMedGoogle Scholar
  126. 126.
    Thapa PB, Meador KG, Gideon P, et al. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 1994; 42: 280–6PubMedGoogle Scholar
  127. 127.
    Horwitz GJ, Tariot PN, Mead K, et al. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 1995; 3: 290–9Google Scholar
  128. 128.
    Kumar V. Use of atypical antipsychotic agents in geriatric patients: a review. Int J Geriatr Psychopharmacol 1997; 1: 15–23Google Scholar
  129. 129.
    Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMedGoogle Scholar
  130. 130.
    Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993; 8: 103–8PubMedGoogle Scholar
  131. 131.
    Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10: 129–36Google Scholar
  132. 132.
    Helms PM. Efficacy of antipsychotics in the treatment of the behavioural complications of dementia: a review of the literature. J Am Geriatr Soc 1985; 33: 206–9PubMedGoogle Scholar
  133. 133.
    Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170–4PubMedGoogle Scholar
  134. 134.
    Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmcol 1982; 2: 122–6Google Scholar
  135. 135.
    Maletta GJ. Pharmacologic treatment and management of the aggressive demented patient. Psychiatric Ann 1990; 20: 446–55Google Scholar
  136. 136.
    Gershanik OS. Drug-induced parkinsonism in the aged: recognition and prevention. Drugs Aging 1994; 5: 127–32PubMedGoogle Scholar
  137. 137.
    Avorn J, Monane M, Everitt DE, et al. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med 1994; 154: 1113–7PubMedGoogle Scholar
  138. 138.
    Wong DF, Wagner HN, Dannais RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393–6PubMedGoogle Scholar
  139. 139.
    Caligiuri MP, Lohr JB, Jeste DV. Instrumental evidence that age increases motor instability in neuroleptic-treated patients. J Gerontol 1991; 46: B197–200PubMedGoogle Scholar
  140. 140.
    Nolan L, OMalley K. Prescribing for the elderly: part I. sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–9PubMedGoogle Scholar
  141. 141.
    Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6PubMedGoogle Scholar
  142. 142.
    Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987; 44: 418–26PubMedGoogle Scholar
  143. 143.
    McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. BMJ 1997; 314: 266–70PubMedGoogle Scholar
  144. 144.
    Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996; 124: 2–34PubMedGoogle Scholar
  145. 145.
    Lacro JP, Eastham JH, Jeste DV, et al. Newer antipsychotics and antidepressants for elderly people. Curr Opin Psychiatry 1996; 9: 290–3Google Scholar
  146. 146.
    Robertsson B, Karlsson I, Eriksson L, et al. An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people. Dementia 1996; 7: 142–6PubMedGoogle Scholar
  147. 147.
    Bymaster FB, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14: 87–96PubMedGoogle Scholar
  148. 148.
    Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinsons disease. Mov Disord 1992; 7: 125–31PubMedGoogle Scholar
  149. 149.
    Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinsons disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996; 8: 276–80PubMedGoogle Scholar
  150. 150.
    Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinsons disease patients. Lancet 1994; 343: 1370–1PubMedGoogle Scholar
  151. 151.
    Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of six patients with Parkinsons disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556–9PubMedGoogle Scholar
  152. 152.
    Jeanblanc W, Davis YB. Risperidone for treating dementia-associated agression [letter]. Am J Psychiatry 1995; 153: 8Google Scholar
  153. 153.
    Marciniak BH, Guay DRP. Risperidone in the long-term care population. Consult Pharm 1995; 10: 1374–8Google Scholar
  154. 154.
    Irizarry MC, Binetti T, Gomez-Isla T, et al. Treatment of behavioral disturbances in dementia with risperidone [abstract]. Neurology 1996; 46: 218Google Scholar
  155. 155.
    Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home resistents: a clinical experience. Int Psychogeriatr 1997; 9: 65–8PubMedGoogle Scholar
  156. 156.
    Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6PubMedGoogle Scholar
  157. 157.
    Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994; 7: 129–32PubMedGoogle Scholar
  158. 158.
    Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56: 180–5PubMedGoogle Scholar
  159. 159.
    Chengappa KNR, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995; 8: 12–5PubMedGoogle Scholar
  160. 160.
    Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedGoogle Scholar
  161. 161.
    Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996; 57Suppl. 3: 39–45PubMedGoogle Scholar
  162. 162.
    Geroldi G, Frisoni B, Bianchetti A, et al. Drug treatment in Lewy body dementia. Dementia Geriatr Cogn Disord 1997; 8: 188–97Google Scholar
  163. 163.
    Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26–33Google Scholar
  164. 164.
    Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients [abstract]. Psychopharmacol Bull 1995; 31: 534Google Scholar
  165. 165.
    Davis R, Markham A. Ziprasidone. CNS Drugs 1997; 8: 153–9Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Gabriela Stoppe
    • 1
  • Claudia A. Brandt
    • 1
  • Jürgen H. Staedt
    • 1
  1. 1.Department of PsychiatryGeorg-August-UniversityGoettingenGermany

Personalised recommendations